Search Results

You are looking at 1 - 10 of 491 items for :

  • Refine by Access: All x
Clear All
Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Overview In 2010, an estimated 68,130 new cases of melanoma were diagnosed and approximately 8700 patients died of the disease in the United States. 1 However, these figures for new cases may represent a substantial underestimation, because

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher K. Bichakjian, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mohammed Kashani-Sabet, Julie R. Lange, Anne Lind, Lainie Martin, Mary C. Martini, Scott K. Pruitt, Merrick I. Ross, Stephen F. Sener, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Jeffrey Weber, and Michael K. Wong

the express written permission of the NCCN © 2009. Disclosures for the NCCN Melanoma Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through

Full access

Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity

Richard D. Carvajal, Sharon A. Spencer, and William Lydiatt

Mucosal melanoma (MM) is an aggressive and clinically complex malignancy made more challenging by its relative rarity. Of the 68,130 cases of melanoma diagnosed in 2010 in the United States, only 0.8% to 1.8% of these arise from mucosal surfaces

Full access

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity

Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, and George Ansstas

Immune checkpoint inhibitors and BRAF-targeted therapies have redefined the management of malignant melanoma. Overall survival (OS) has increased significantly with immunotherapy, with >60 months reported. 1 Stabilization of the survival curve in

Full access

Update on Immunotherapy for Melanoma

Antoni Ribas

The author was supported in part by K23 CA93376 and the Melanoma Research Foundation during the preparation of this manuscript. References 1. Blattman JN Greenberg PD . Cancer immunotherapy: a treatment for the masses

Full access

Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Leslie A. Fecher and Keith T. Flaherty

Clinical Practice Guidelines in Oncology: Melanoma. NCCN Practice Guidelines in Oncology, Version 2, 2008 . Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf . Accessed January 20, 2009 . 4 Balch C Buzaid A Soong S

Full access

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Marc Ernstoff, Ryan C. Fields, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Merrick I. Ross, April K. Salama, Joseph Skitzki, Jeff Sosman, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States. 1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

No benefits or funds were received in support of this study. References 1 Balch CM Buzaid AC Soong S-J . Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma . J Clin Oncol 2001 ; 19

Full access

The Economic Impact of Non-Melanoma Skin Cancer: A Review

Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman

N on-melanoma skin cancers (NMSCs), characterized by malignant growth of the epithelial layer or external surface of the skin, are the most prevalent form of skin cancer in the United States. 1 Since the 1960s, the incidence of NMSC has increased

Full access

Melanoma, Version 4.2014

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho

: Integrate into professional practice the updates to NCCN Guidelines for Melanoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma NCCN Categories of Evidence and Consensus Category 1: Based